Heron Therapeutics (NASDAQ:HRTX) has been given a $31.00 price target by stock analysts at Cantor Fitzgerald in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 67.12% from the company’s current price.

Several other research analysts have also weighed in on HRTX. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Leerink Swann assumed coverage on shares of Heron Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $22.00 price target on the stock. Mizuho assumed coverage on shares of Heron Therapeutics in a research note on Tuesday, September 26th. They set a “buy” rating and a $28.00 price target on the stock. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Finally, Northland Securities assumed coverage on shares of Heron Therapeutics in a research note on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price target on the stock. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $28.82.

Heron Therapeutics (NASDAQ HRTX) opened at $18.55 on Friday. The firm has a market cap of $1,190.52, a P/E ratio of -4.89 and a beta of 2.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $19.55.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities research analysts expect that Heron Therapeutics will post -3.39 earnings per share for the current year.

A number of large investors have recently bought and sold shares of HRTX. Legal & General Group Plc boosted its holdings in Heron Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 2,383 shares during the period. Quantbot Technologies LP boosted its holdings in Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 12,024 shares during the period. Trexquant Investment LP bought a new stake in Heron Therapeutics in the 3rd quarter valued at $206,000. Jane Street Group LLC bought a new stake in Heron Therapeutics in the 3rd quarter valued at $223,000. Finally, HighTower Advisors LLC boosted its holdings in Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 1,700 shares during the period. Institutional investors and hedge funds own 98.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $31.00 Price Target” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-heron-therapeutics-hrtx-a-31-00-price-target/1797261.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.